optio semaglutide/niacinamide Semaglutide (ozempic) before & after 🤍 Evidence-based, GLP-1 receptor agonist therapy designed to support glycemic control and sustained weight loss. Remember, it's about feeling good from the inside out 💫 As a Ozempic® | GoodGirlRx

Medications affecting sympathetic activity (like certain antidepressants) or blood sugar control may complicate combined use

262, e230405

GLP-1 is rapidly degraded by an enzyme named dipeptidyl peptidase-IV (DPP-4), converting to bioinactive products GLP-1 (9-36) and GLP-1 (9-37) ( GLP-1 exerts its function by binding to GLP-1R and is involved in the development and progression of many diseases ( GLP-1R agonists (GLP-1RAs) are a group of GLP-1 analogues that are resistant to DPP4-mediated degradation, working through activating GLP-1R and its downstream signaling ( The expression of GLP-1R remains controversial due to the lack of specific antibody against GLP-1R, with most of the literatures using qPCR to detect mRNA levels ( 2 GLP-1 in regulating immune system 2.1 The role of GLP-1 in innate immune cells Recent studies have demonstrated that GLP-1 and its analogues exert regulatory functions in innate immune cells, especially macrophages

Brun, P

Gastrointestinal effects are the most frequently reported side effects and include: Nausea (1224% of patients): Often most pronounced during treatment initiation and dose escalation, typically improving over time Diarrhea (1323% of patients): May be transient or persistent, requiring dietary modifications Vomiting (611% of patients): Can lead to dehydration if severe or prolonged Constipation (617% of patients): May require increased fiber intake and hydration Abdominal pain or discomfort (610% of patients): Usually mild to moderate in severity Decreased appetite : Therapeutic effect but may be excessive in some individuals These gastrointestinal symptoms generally diminish over several weeks as the body adjusts to the medication

PubChem Compound Summary for CID 171390338, Retatrutide